Report cover image

TB Diagnostic Market By Type (Culture based diagnosis, Sputum test, Rapid Molecular Diagnosis, Others), By End-User (Hospitals, Diagnostic labs, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

Publisher Allied Market Research
Published Sep 02, 2023
Length 250 Pages
SKU # ALMR18790739

Description

TB Diagnostic Market By Type (Culture based diagnosis, Sputum test, Rapid Molecular Diagnosis, Others), By End-User (Hospitals, Diagnostic labs, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032


The TB Diagnostic Market was valued for $2,066.70 million in 2022 and is estimated to reach $3,102.20 million by 2032, exhibiting a CAGR of 4.1% from 2023 to 2032.

Tuberculosis (TB) is a bacterial infection caused by mycobacterium tuberculosis that primarily affects the lungs. It is a bacterial infection spread through inhaling tiny droplets from the coughs or sneezes of an infected person. TB is mainly diagnosed with the TB skin test (TST) and TB blood tests.

The growth of the TB diagnostic market is driven by an increase in the number of R&D activities, the surge in expenditure on product development by the government & private organizations, increase in the technological advancements of the diagnostics test’s products, and an upsurge in the number of hospital visits of the patients for TB screening. Furthermore, the increase in the prevalence of Tb infection drives the growth of the market. For instance, according to the World Health Organization (WHO), in 2021, an estimated 10.6 million people fell ill with tuberculosis (TB) worldwide.

Moreover, an increase in the research pipeline among diagnostic research organizations and rise in awareness about early tuberculosis screening help in the growth of the market. Furthermore, increase in number of product approval and product launch foster the expansion of the market. For instance, in February 2022, QIAGEN N.V., a leading diagnostic company, announced that its QuantiFERON-TB Gold Plus (QFT-Plus), the fourth generation of the modern gold standard for TB detection, received Chinese NMPA approval as test for active tuberculosis detection.

However, BCG vaccination, inaccurate pap smear testing, and the availability of other types of screening for TB are expected to hinder the growth of the market.

The TB diagnostic market is segmented on the basis of type, end user, and region. On the basis of type, the market is categorized into culture-based diagnosis, sputum smear test, rapid molecular diagnosis, and others. On the basis of end user, the market is classified into hospitals, diagnostic labs, and others. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major companies profiled in the report include Abbott Laboratories, Becton Dickinson and Company, Biomerieux SA, Molbio Diagnostics, Bio-Rad Laboratories, Danaher Corporation, F. Hoffmon La-Roche, Hologic Inc., Qiagen Inc and ThermoFisher Scientific.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the tb diagnostic market analysis from 2022 to 2032 to identify the prevailing tb diagnostic market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the tb diagnostic market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global tb diagnostic market trends, key players, market segments, application areas, and market growth strategies.
New Product Development/ Product Matrix of Key Players
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Criss-cross segment analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)
SWOT Analysis

Key Market Segments

By Type

Culture based diagnosis
Sputum test
Rapid Molecular Diagnosis
Others

By End-User

Hospitals
Diagnostic labs
Others

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

Key Market Players

Abbott Laboratories
Becton Dickinson & Company
Molbio Diagnostics Pvt. Ltd.
Bio-Rad Laboratories, Inc.
Danaher Corporation
Hologic Inc.
Thermo Fisher Scientific Inc.
bioMerieux SA
F. Hoffmann-La Roche Ltd.
Qiagen NV.

Please Note: It will take 7-10 business days to complete the report upon order confirmation. 

Table of Contents

250 Pages
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Moderate threat of new entrants
3.3.3. Moderate threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in the prevalence of tuberculosis
3.4.1.2. Rise in healthcare expenditure and improvements in healthcare facilities
3.4.1.3. Growth in initiatives from government organizations for tuberculosis awareness
3.4.2. Restraints
3.4.2.1. Lack of awareness about TB
3.4.3. Opportunities
3.4.3.1. High growth potential in developing economies
CHAPTER 4: TB DIAGNOSTIC MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Culture based diagnosis
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Sputum test
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Rapid Molecular Diagnosis
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Others
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
CHAPTER 5: TB DIAGNOSTIC MARKET, BY END-USER
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospitals
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Diagnostic labs
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Others
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: TB DIAGNOSTIC MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast By Region
6.2. North America
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by Type
6.2.3. Market size and forecast, by End-User
6.2.4. Market size and forecast, by country
6.2.4.1. U.S.
6.2.4.1.1. Market size and forecast, by Type
6.2.4.1.2. Market size and forecast, by End-User
6.2.4.2. Canada
6.2.4.2.1. Market size and forecast, by Type
6.2.4.2.2. Market size and forecast, by End-User
6.2.4.3. Mexico
6.2.4.3.1. Market size and forecast, by Type
6.2.4.3.2. Market size and forecast, by End-User
6.3. Europe
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by Type
6.3.3. Market size and forecast, by End-User
6.3.4. Market size and forecast, by country
6.3.4.1. Germany
6.3.4.1.1. Market size and forecast, by Type
6.3.4.1.2. Market size and forecast, by End-User
6.3.4.2. France
6.3.4.2.1. Market size and forecast, by Type
6.3.4.2.2. Market size and forecast, by End-User
6.3.4.3. UK
6.3.4.3.1. Market size and forecast, by Type
6.3.4.3.2. Market size and forecast, by End-User
6.3.4.4. Italy
6.3.4.4.1. Market size and forecast, by Type
6.3.4.4.2. Market size and forecast, by End-User
6.3.4.5. Spain
6.3.4.5.1. Market size and forecast, by Type
6.3.4.5.2. Market size and forecast, by End-User
6.3.4.6. Rest of Europe
6.3.4.6.1. Market size and forecast, by Type
6.3.4.6.2. Market size and forecast, by End-User
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by Type
6.4.3. Market size and forecast, by End-User
6.4.4. Market size and forecast, by country
6.4.4.1. China
6.4.4.1.1. Market size and forecast, by Type
6.4.4.1.2. Market size and forecast, by End-User
6.4.4.2. Japan
6.4.4.2.1. Market size and forecast, by Type
6.4.4.2.2. Market size and forecast, by End-User
6.4.4.3. India
6.4.4.3.1. Market size and forecast, by Type
6.4.4.3.2. Market size and forecast, by End-User
6.4.4.4. Australia
6.4.4.4.1. Market size and forecast, by Type
6.4.4.4.2. Market size and forecast, by End-User
6.4.4.5. South Korea
6.4.4.5.1. Market size and forecast, by Type
6.4.4.5.2. Market size and forecast, by End-User
6.4.4.6. Rest of Asia-Pacific
6.4.4.6.1. Market size and forecast, by Type
6.4.4.6.2. Market size and forecast, by End-User
6.5. LAMEA
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by Type
6.5.3. Market size and forecast, by End-User
6.5.4. Market size and forecast, by country
6.5.4.1. Brazil
6.5.4.1.1. Market size and forecast, by Type
6.5.4.1.2. Market size and forecast, by End-User
6.5.4.2. Saudi Arabia
6.5.4.2.1. Market size and forecast, by Type
6.5.4.2.2. Market size and forecast, by End-User
6.5.4.3. South Africa
6.5.4.3.1. Market size and forecast, by Type
6.5.4.3.2. Market size and forecast, by End-User
6.5.4.4. Rest of LAMEA
6.5.4.4.1. Market size and forecast, by Type
6.5.4.4.2. Market size and forecast, by End-User
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top player positioning, 2022
CHAPTER 8: COMPANY PROFILES
8.1. Abbott Laboratories
8.1.1. Company overview
8.1.2. Key Executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.2. Becton Dickinson & Company
8.2.1. Company overview
8.2.2. Key Executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.3. Molbio Diagnostics Pvt. Ltd.
8.3.1. Company overview
8.3.2. Key Executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.4. Bio-Rad Laboratories, Inc. 
8.4.1. Company overview
8.4.2. Key Executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.5. Danaher Corporation
8.5.1. Company overview
8.5.2. Key Executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.6. Hologic Inc.
8.6.1. Company overview
8.6.2. Key Executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.7. Qiagen NV.
8.7.1. Company overview
8.7.2. Key Executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.8. Thermo Fisher Scientific Inc.
8.8.1. Company overview
8.8.2. Key Executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.9. bioMerieux SA
8.9.1. Company overview
8.9.2. Key Executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.10. F. Hoffmann-La Roche Ltd.
8.10.1. Company overview
8.10.2. Key Executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance
LIST OF TABLES
TABLE 01. GLOBAL TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 02. TB DIAGNOSTIC MARKET FOR CULTURE BASED DIAGNOSIS, BY REGION, 2022-2032 ($MILLION)
TABLE 03. TB DIAGNOSTIC MARKET FOR SPUTUM TEST, BY REGION, 2022-2032 ($MILLION)
TABLE 04. TB DIAGNOSTIC MARKET FOR RAPID MOLECULAR DIAGNOSIS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. TB DIAGNOSTIC MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 06. GLOBAL TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)
TABLE 07. TB DIAGNOSTIC MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
TABLE 08. TB DIAGNOSTIC MARKET FOR DIAGNOSTIC LABS, BY REGION, 2022-2032 ($MILLION)
TABLE 09. TB DIAGNOSTIC MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 10. TB DIAGNOSTIC MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 11. NORTH AMERICA TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 12. NORTH AMERICA TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)
TABLE 13. NORTH AMERICA TB DIAGNOSTIC MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 14. U.S. TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 15. U.S. TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)
TABLE 16. CANADA TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 17. CANADA TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)
TABLE 18. MEXICO TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 19. MEXICO TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)
TABLE 20. EUROPE TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 21. EUROPE TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)
TABLE 22. EUROPE TB DIAGNOSTIC MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 23. GERMANY TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 24. GERMANY TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)
TABLE 25. FRANCE TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 26. FRANCE TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)
TABLE 27. UK TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 28. UK TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)
TABLE 29. ITALY TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 30. ITALY TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)
TABLE 31. SPAIN TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 32. SPAIN TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)
TABLE 33. REST OF EUROPE TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 34. REST OF EUROPE TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)
TABLE 35. ASIA-PACIFIC TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 36. ASIA-PACIFIC TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)
TABLE 37. ASIA-PACIFIC TB DIAGNOSTIC MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 38. CHINA TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 39. CHINA TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)
TABLE 40. JAPAN TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 41. JAPAN TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)
TABLE 42. INDIA TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 43. INDIA TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)
TABLE 44. AUSTRALIA TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 45. AUSTRALIA TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)
TABLE 46. SOUTH KOREA TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 47. SOUTH KOREA TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)
TABLE 48. REST OF ASIA-PACIFIC TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 49. REST OF ASIA-PACIFIC TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)
TABLE 50. LAMEA TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 51. LAMEA TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)
TABLE 52. LAMEA TB DIAGNOSTIC MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 53. BRAZIL TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 54. BRAZIL TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)
TABLE 55. SAUDI ARABIA TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 56. SAUDI ARABIA TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)
TABLE 57. SOUTH AFRICA TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 58. SOUTH AFRICA TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)
TABLE 59. REST OF LAMEA TB DIAGNOSTIC MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 60. REST OF LAMEA TB DIAGNOSTIC MARKET, BY END-USER, 2022-2032 ($MILLION)
TABLE 61. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 62. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 63. ABBOTT LABORATORIES: PRODUCT SEGMENTS
TABLE 64. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 65. BECTON DICKINSON & COMPANY: KEY EXECUTIVES
TABLE 66. BECTON DICKINSON & COMPANY: COMPANY SNAPSHOT
TABLE 67. BECTON DICKINSON & COMPANY: PRODUCT SEGMENTS
TABLE 68. BECTON DICKINSON & COMPANY: PRODUCT PORTFOLIO
TABLE 69. MOLBIO DIAGNOSTICS PVT. LTD.: KEY EXECUTIVES
TABLE 70. MOLBIO DIAGNOSTICS PVT. LTD.: COMPANY SNAPSHOT
TABLE 71. MOLBIO DIAGNOSTICS PVT. LTD.: PRODUCT SEGMENTS
TABLE 72. MOLBIO DIAGNOSTICS PVT. LTD.: PRODUCT PORTFOLIO
TABLE 73. BIO-RAD LABORATORIES, INC. : KEY EXECUTIVES
TABLE 74. BIO-RAD LABORATORIES, INC. : COMPANY SNAPSHOT
TABLE 75. BIO-RAD LABORATORIES, INC. : PRODUCT SEGMENTS
TABLE 76. BIO-RAD LABORATORIES, INC. : PRODUCT PORTFOLIO
TABLE 77. DANAHER CORPORATION: KEY EXECUTIVES
TABLE 78. DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 79. DANAHER CORPORATION: PRODUCT SEGMENTS
TABLE 80. DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 81. HOLOGIC INC.: KEY EXECUTIVES
TABLE 82. HOLOGIC INC.: COMPANY SNAPSHOT
TABLE 83. HOLOGIC INC.: PRODUCT SEGMENTS
TABLE 84. HOLOGIC INC.: PRODUCT PORTFOLIO
TABLE 85. QIAGEN NV.: KEY EXECUTIVES
TABLE 86. QIAGEN NV.: COMPANY SNAPSHOT
TABLE 87. QIAGEN NV.: PRODUCT SEGMENTS
TABLE 88. QIAGEN NV.: PRODUCT PORTFOLIO
TABLE 89. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
TABLE 90. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
TABLE 91. THERMO FISHER SCIENTIFIC INC.: PRODUCT SEGMENTS
TABLE 92. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
TABLE 93. BIOMERIEUX SA: KEY EXECUTIVES
TABLE 94. BIOMERIEUX SA: COMPANY SNAPSHOT
TABLE 95. BIOMERIEUX SA: PRODUCT SEGMENTS
TABLE 96. BIOMERIEUX SA: PRODUCT PORTFOLIO
TABLE 97. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 98. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 99. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 100. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. TB DIAGNOSTIC MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF TB DIAGNOSTIC MARKET,2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN TB DIAGNOSTIC MARKET (2023-2032)
FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 05. MODERATE THREAT OF NEW ENTRANTS
FIGURE 06. MODERATE THREAT OF SUBSTITUTES
FIGURE 07. MODERATE INTENSITY OF RIVALRY
FIGURE 08. MODERATE BARGAINING POWER OF BUYERS
FIGURE 09. GLOBAL TB DIAGNOSTIC MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 10. TB DIAGNOSTIC MARKET, BY TYPE, 2022 AND 2032(%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF TB DIAGNOSTIC MARKET FOR CULTURE BASED DIAGNOSIS, BY COUNTRY 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF TB DIAGNOSTIC MARKET FOR SPUTUM TEST, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF TB DIAGNOSTIC MARKET FOR RAPID MOLECULAR DIAGNOSIS, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF TB DIAGNOSTIC MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. TB DIAGNOSTIC MARKET, BY END-USER, 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF TB DIAGNOSTIC MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF TB DIAGNOSTIC MARKET FOR DIAGNOSTIC LABS, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF TB DIAGNOSTIC MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. TB DIAGNOSTIC MARKET BY REGION, 2022 AND 2032(%)
FIGURE 20. U.S. TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 21. CANADA TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 22. MEXICO TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 23. GERMANY TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 24. FRANCE TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 25. UK TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 26. ITALY TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 27. SPAIN TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 28. REST OF EUROPE TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 29. CHINA TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 30. JAPAN TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 31. INDIA TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 32. AUSTRALIA TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 33. SOUTH KOREA TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 34. REST OF ASIA-PACIFIC TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 35. BRAZIL TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 36. SAUDI ARABIA TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 37. SOUTH AFRICA TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 38. REST OF LAMEA TB DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 39. TOP WINNING STRATEGIES, BY YEAR
FIGURE 40. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 41. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 42. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 43. COMPETITIVE DASHBOARD
FIGURE 44. COMPETITIVE HEATMAP: TB DIAGNOSTIC MARKET
FIGURE 45. TOP PLAYER POSITIONING, 2022
FIGURE 46. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
FIGURE 47. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 48. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 49. BECTON DICKINSON & COMPANY: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 50. BECTON DICKINSON & COMPANY: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)
FIGURE 51. BECTON DICKINSON & COMPANY: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 52. BECTON DICKINSON & COMPANY: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 53. BIO-RAD LABORATORIES, INC. : NET SALES, 2020-2022 ($MILLION)
FIGURE 54. BIO-RAD LABORATORIES, INC. : REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 55. BIO-RAD LABORATORIES, INC. : REVENUE SHARE BY REGION, 2022 (%)
FIGURE 56. DANAHER CORPORATION: NET SALES, 2020-2022 ($MILLION)
FIGURE 57. DANAHER CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 58. DANAHER CORPORATION: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 59. HOLOGIC INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 60. HOLOGIC INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 61. HOLOGIC INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 62. QIAGEN NV.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 63. QIAGEN NV.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 64. QIAGEN NV.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 65. THERMO FISHER SCIENTIFIC, INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 66. THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 67. THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 68. BIOMERIEUX SA: NET SALES, 2020-2022 ($MILLION)
FIGURE 69. BIOMERIEUX SA: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 70. BIOMERIEUX SA: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 71. F. HOFFMANN-LA ROCHE LTD.: NET SALES, 2020-2022 ($MILLION)
FIGURE 72. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 73. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2022 (%)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us